Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual eating disorder treatment using family-based therapy, San Diego CA, raised $58M+. First at-home model for anorexia and bulimia treatment in the US.
Equip Health is a San Diego, California-based virtual care company founded in 2019 that specializes in treating eating disorders including anorexia, bulimia, binge eating disorder, and avoidant restrictive food intake disorder (ARFID). The company has raised over $58 million and has pioneered a virtual delivery model for family-based treatment (FBT), the gold-standard evidence-based therapy for adolescent eating disorders, making intensive evidence-based care accessible outside of residential treatment programs.\n\nEquip's care model assembles a five-person care team for each patient: a therapist, a dietitian, a physician, a family mentor, and a peer mentor — all coordinating through the platform. This team-based virtual approach mirrors the multidisciplinary structure of leading eating disorder treatment centers while eliminating the geographic and financial barriers that prevent most patients from accessing residential care. Sessions are conducted by video with the patient and their family, with meal support and between-session coaching embedded in the program.\n\nThe company distributes its services through insurance coverage, accepting major commercial plans and working to expand Medicaid coverage. Eating disorders carry the highest mortality rate of any psychiatric illness, yet treatment access is severely limited in the United States. Equip's virtual model has treated patients across all 50 states, demonstrating the feasibility of delivering intensive eating disorder care at home and positioning the company as a national provider in a historically fragmented specialty.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.